All In Biotech

Drug Trial Radar · NCT04542070

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed

Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 687 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

687

Actual

Start

Nov 9, 2020

Primary completion

Jul 13, 2022

Study completion Apr 17, 2023

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Janssen, LP
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.

Conditions

  • HIV Infections

Interventions

  • Cabotegravir TabletsDrug

    CAB tablets were available as film coated tablets for oral administration.

  • Cabotegravir Injectable Suspension (CAB LA)Drug

    CAB LA was available as sterile suspension for injection in GSK1265744 for administration as IM injection.

  • Rilpivirine TabletsDrug

    RPV was administered as tablets for oral administration.

  • Rilpivirine Injectable Suspension (RPV LA)Drug

    RPV LA was available as a sterile suspension of RPV to be administered as an IM injection.

  • BIKTARVY Tablets (BIK)Drug

    BIK was a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Plasma Human Immunodeficiency Viruses (HIV)-1 Ribonucleic Acid (RNA) Greater Than or Equal to (>=) 50 Copies Per Milliliter (c/mL) at Month 12/11 - ITT-E PopulationTime frame: At month 12/11
  2. Percentage of Participants With Plasma HIV-1 RNA Greater >=50 Copies Per Milliliter (c/mL) at Month 12/11 - mITT-E PopulationTime frame: At month 12/11

Locations

117 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Kansas City, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Southfield, Michigan

  • GSK Investigational Site

    Newark, New Jersey

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Greenville, North Carolina

  • GSK Investigational Site

    Huntersville, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Toledo, Ohio

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Bellaire, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Seattle, Washington

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.